Show simple item record Ryan, Aidan Godson, Catherine 2010-08-19T14:22:41Z 2010-08-19T14:22:41Z Copyright 2010 Elsevier Ltd en 2010-04
dc.identifier.citation Current Opinion in Pharmacology en
dc.identifier.issn 1471-4892
dc.description.abstract Persistent inflammation underlies many of the most prevalent diseases in the developed world including atherosclerosis and diabetes. There is a growing appreciation that inflammation and its active resolution may be modulated by endogenously produced lipid mediators. Preeminent amongst these mediators are the lipoxins [LX]. The acronym lipoxin describes the provenance of these mediators: lipoxygenase interacting products . The LX are eicosanoids and display both anti-inflammatory and pro-resolving bioactions. More recently other pro-resolving lipid mediators have been described including the resolvins and neuroprotectins. In effective host defence LX biosynthesis is characterised by a switch from pro-inflammatory prostaglandin and leukotriene (LT) generation from arachidonic acid (AA) to LX production coincident with a return to tissue homeostasis ( see figure 1). Here we will provide an overview of LX pharmacokinetics, bioactions and summarise the evidence to date that indicates that LX are potential therapeutic agents for disorders involving cardiovascular and renal inflammation, leading to tissue damage and organ fibrosis. en
dc.description.sponsorship Science Foundation Ireland en
dc.description.sponsorship Higher Education Authority en
dc.format.extent 806700 bytes
dc.format.mimetype application/pdf
dc.language.iso en en
dc.publisher Elsevier en
dc.rights All rights reserved en
dc.subject Lipoxins en
dc.subject Renal inflammation en
dc.subject Resolution of inflammation en
dc.subject.lcsh Lipoxins--Therapeutic use en
dc.subject.lcsh Inflammation--Mediators en
dc.subject.lcsh Lipoxins--Pharmacokinetics en
dc.subject.mesh Lipoxins--therapeutic use en
dc.subject.mesh Inflammation Mediators en
dc.title Lipoxins : regulators of resolution en
dc.type Journal Article en
dc.internal.availability Full text available en
dc.internal.webversions en
dc.status Peer reviewed en
dc.identifier.volume 10 en
dc.identifier.issue 2 en
dc.identifier.startpage 166 en
dc.identifier.endpage 172 en
dc.identifier.doi 10.1016/j.coph.2010.02.005
dc.neeo.contributor Ryan|Aidan|aut| en
dc.neeo.contributor Godson|Catherine|aut| en
dc.description.othersponsorship Wellcome trust en
dc.description.othersponsorship Health Research Board en
dc.description.admin Record must link to the DOI version of the article - DG 05/07/10 PMID: 20226737. ti sp ke ab jo - 100729 RB. en

This item appears in the following Collection(s)

Show simple item record

This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

If you are a publisher or author and have copyright concerns for any item, please email and the item will be withdrawn immediately. The author or person responsible for depositing the article will be contacted within one business day.

Search Research Repository

Advanced Search